Back to results
US 9,079,948 B2Granted
Human antibodies to Fel d1 and methods of use thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJamie Orengo, Andrew J. Murphy
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJamie Orengo, Andrew J. Murphy
Estimating the term…
The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.
An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within the heavy chain variable region (HCVR) sequence of SEQ ID NO:
An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to Fel d1, wherein the antibody comprises:
A pharmaceutical composition comprising the human antibody or an antigen-binding fragment thereof having the HCVR/LCVR amino acid sequence pair of SEQ ID NOs:
Dependencies are inferred from the claim text.